Skip to main content

Ertugliflozin Disease Interactions

There are 4 disease interactions with ertugliflozin.

Major

SGLT-2 inhibitors (applies to ertugliflozin) liver dysfunction

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data. Sotagliflozin is not recommended for use in patients with moderate to severe hepatic impairment. Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended. The manufacturer's product labeling should be consulted for specific dosing of SGLT2 inhibitors in patients with hepatic impairment.

References

  1. "Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals (2013):
  2. "Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb (2014):
  3. "Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc (2017):
  4. "Product Information. Inpefa (sotagliflozin)." Lexicon Pharmaceuticals, Inc. (2023):
View all 4 references
Major

SGLT2 inhibitors (applies to ertugliflozin) renal dysfunction

Major Potential Hazard, Moderate plausibility.

The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors are decreased in patients with worsening renal function. Additionally, patients with impaired renal function (estimated GFR less than 60 mL/min/1.73 m2), older adult patients, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy. Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients. Volume status should be assessed and volume depletion corrected before initiating therapy. The use of SGLT2 inhibitors in patients undergoing dialysis is either contraindicated or not recommended. The manufacturer product information should be consulted for contraindications and indication specific renal dosing.

References

  1. "Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals (2013):
  2. "Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb (2014):
  3. "Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc (2017):
  4. "Product Information. Inpefa (sotagliflozin)." Lexicon Pharmaceuticals, Inc. (2023):
  5. "Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim SUPPL-42 (2023):
View all 5 references
Moderate

SGLT2 inhibitors (applies to ertugliflozin) hypotension

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Sodium-glucose cotransporter 2 (SGLT2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation, especially in older adult patients, patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics. Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.

References

  1. "Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals (2013):
  2. "Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb (2014):
  3. "Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc (2017):
  4. "Product Information. Inpefa (sotagliflozin)." Lexicon Pharmaceuticals, Inc. (2023):
  5. "Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim SUPPL-42 (2023):
View all 5 references
Moderate

SGLT2 inhibitors (applies to ertugliflozin) infections

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Sodium-glucose cotransporter 2 (SGLT2) inhibitors increase the risk of genital mycotic infections. Care should be exercised when using an SGLT2 inhibitor in patients who have a history of chronic or recurrent genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections. Patients should be monitored and treated appropriately.

References

  1. "Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc (2017):
  2. "Product Information. Inpefa (sotagliflozin)." Lexicon Pharmaceuticals, Inc. (2023):
  3. "Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim SUPPL-42 (2023):

Ertugliflozin drug interactions

There are 354 drug interactions with ertugliflozin.

Ertugliflozin alcohol/food interactions

There is 1 alcohol/food interaction with ertugliflozin.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer